Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference

News provided by

Array BioPharma Inc.

Aug 30, 2018, 16:05 ET

BOULDER, Colo., Aug. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Wells Fargo Securities 2018 Healthcare Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

Event:          

Wells Fargo Securities 2018 Healthcare Conference

Presenter:    

Ron Squarer, Chief Executive Officer, Array BioPharma

Date:              

Thursday, September 6, 2018

Time:            

3:05 p.m. Eastern Time

Webcast:       

https://cc.talkpoint.com/well001/090518a_as/?entity=47_0GHY12N

About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets in the United States BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including selumetinib (partnered with AstraZeneca), larotrectinib (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797 (being developed by Yarra Therapeutics, a wholly-owned subsidiary of Array), all of which are currently in registration trials. Ganovo® (danoprevir, partnered with Roche) was recently approved in China for the treatment of viral hepatitis C. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:       
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
[email protected]

SOURCE Array BioPharma Inc.

Related Links

http://www.arraybiopharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED